A Clopidogrel-Insensitive Inducible Pool of P2Y12 Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y12 Antagonist

被引:22
|
作者
Haberstock-Debic, Helena [1 ]
Andre, Patrick [1 ]
Mills, Scott [1 ]
Phillips, David R. [1 ]
Conley, Pamela B. [1 ]
机构
[1] Portola Pharmaceut Inc, San Francisco, CA 94080 USA
关键词
PERCUTANEOUS CORONARY INTERVENTION; VARIABILITY; PLATELETS; ASPIRIN; PRETREATMENT; ACTIVATION; METABOLITE; TARGET;
D O I
10.1124/jpet.111.184143
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It is known that hepatic metabolism limits the antiaggregatory activity of clopidogrel and, as a consequence, its clinical benefits. In this study, we investigated whether other factors exist that could account for clopidogrel's suboptimal antithrombotic activity. Using an in vivo murine FeCl3 thrombosis model coupled with intravital microscopy, we found that at equivalent, maximal levels of inhibition of ADP-induced platelet aggregation, clopidogrel (50 mg/kg p.o.) failed to reproduce the phenotype associated with P2Y(12) deficiency. However, elinogrel (60 mg/kg p.o.), a direct-acting reversible P2Y(12) antagonist, achieved maximal levels of inhibition in vivo, and its administration (1 mg/kg i.v.) abolished residual thrombosis associated with clopidogrel dosing. Because elinogrel is constantly present in the plasma, whereas the active metabolite of clopidogrel exists for similar to 2 h, we evaluated whether an intracellular pool of P2Y(12) exists that would be inaccessible to clopidogrel and contribute to its limited antithrombotic activity. Using saturation [H-3]2-(methylthio) ADP ([H-3]2MeSADP) binding studies, we first demonstrated that platelet stimulation with thrombin and convulxin (mouse) and thrombin receptor activating peptide (TRAP) (human) significantly increased surface expression of P2Y(12) relative to that of resting platelets. We next found that clopidogrel dose-dependently inhibited ADP-induced aggregation, signaling (cAMP), and surface P2Y(12) on resting mouse platelets, achieving complete inhibition at the highest dose (50 mg/kg), but failed to block this inducible pool. Thus, an inducible pool of P2Y(12) exists on platelets that can be exposed upon platelet activation by strong agonists. This inducible pool is not blocked completely by clopidogrel, contributes to thrombosis in vivo, and can be blocked by elinogrel.
引用
收藏
页码:54 / 61
页数:8
相关论文
共 50 条
  • [1] The clopidogrel-insensitive pool of P2Y12 receptors exposed upon platelet activation contributes to thrombus formation and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor
    Haberstock-Debic, H.
    Andre, P.
    Delaney, S.
    Mills, S.
    Pak, Y.
    Phillips, D.
    Conley, P.
    EUROPEAN HEART JOURNAL, 2009, 30 : 884 - 884
  • [2] A functional pool of P2Y12 receptors exposed upon platelet activation persists in mice treated with high dose clopidogrel, and can be blocked by elinogrel, a direct acting, reversible P2Y12 inhibitor
    Haberstock-Debic, H.
    Andre, P.
    Delaney, S. M.
    Mills, S.
    Pak, Y.
    Phillips, D. R.
    Conley, P. B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 331 - 331
  • [3] The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor
    Bouman, Heleen J.
    van Werkum, Jochem W.
    Rudez, Goran
    Leebeek, Frank W. G.
    Kruit, Adrian
    Hackeng, Christian M.
    ten Berg, Jurrien M.
    de Maat, Moniek P. M.
    Ruven, Henk J. T.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (02) : 379 - 386
  • [4] The influence of variation in the P2Y12 receptor gene on the magnitude of in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor
    Bouman, H. J.
    van Werkum, J. W.
    Rudez, G.
    Leebeek, F. W. G.
    Kruit, A.
    Hackeng, C. M.
    ten Berg, J. M.
    de Maat, M. P. M.
    Ruven, H. J. T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 587 - 588
  • [5] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [6] The Role of Direct-Acting P2Y12 Inhibitors in Acute Coronary Syndrome
    Buryakina, T. A.
    Zateyshchikov, D. A.
    KARDIOLOGIYA, 2012, 52 (04) : 74 - 79
  • [7] P2Y12 Receptors In Ischemic Inflammation: A New Role For Clopidogrel?
    Webster, Carla
    McManus, April
    Hokari, Masaaki
    Tang, Xian Nan
    Yenari, Midori A.
    STROKE, 2011, 42 (03) : E296 - E296
  • [8] Antiplatelet Therapy n ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors
    Ristorto, Jessica
    Messas, Nathan
    Marchandot, Benjamin
    Kibler, Marion
    Hess, Sebastien
    Meyer, Nicolas
    Schaeffer, Michael
    Tuzin, Nicolas
    Ohlmann, Patrick
    Jesel, Laurence
    Morel, Olivier
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2018, 25 (08) : 674 - 689
  • [9] P2Y12 receptors: structure and function
    Cattaneo, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : S10 - S16
  • [10] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537